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doi:10.1Objective: Clinical outcomes have been investigated extensively in studies of esophageal cancer treatment. Less
is known about long-term health-related quality of life outcomes. The aim of this study was to assess a range of
health-related quality of life outcomes in patients with esophageal cancer treated with potentially curative intent at
least 1 year earlier.
Methods: Between January 1995 and December 2007, 163 consecutive patients with cancer of the esophagus
underwent a potentially curative treatment. All patients with a minimal follow-up of 1 year and without tumor
recurrence were eligible. Questionnaires included the European Organization for Research and Treatment of Can-
cer core questionnaire (QLQ-C30), the European Organization for Research and Treatment of Cancer esophageal
cancer-specific questionnaire (QLQ-OES18), and additional questions concerning survivorship issues.
Results: Thirty-seven patients met the inclusion criteria, of whom 36 completed the questionnaires. Twenty-one
patients had received neoadjuvant therapy followed by surgery, 9 patients had undergone surgery only, and 6
patients had chemoradiation only. Median survival was 54 (range, 16–162) months. In general, patients reported
better health-related quality of life than a reference sample of patients with esophageal cancer, but somewhat com-
promised health-related quality of life compared with a reference sample of individuals from the general popu-
lation. Although some symptoms continued to persist, patients’ overall evaluation on their treatment, employment
status and finances, body weight and image, and survivorship issues was positive.
Conclusions: Patients who survive 1 year or more after potentially curative treatment for esophageal cancer can
lead satisfactory lives. The results of this study can be used when informing patients with esophageal cancer about
the long-term effects of treatment. (J Thorac Cardiovasc Surg 2010;140:777-83)In patients with resectable esophageal cancer, surgery is rec-
ommended to cure the disease, and when that is not possible,
to relieve symptoms and to prolong life. Length of (disease-
free) survival is the most important clinical outcome para-
meter. Esophageal resection can also have serious negative
effects on health-related quality of life (HRQoL), although
after an initial postoperative decline, HRQoL often returns
to baseline levels within 1 year after surgery.1–5 In the
long-term, no significant differences have been observed
in HRQoL as a function of type of surgery (ie, transhiatal
vs transthoracic resection).6
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The Journal of Thoracic and CaHRQoL outcomes. Most tumor recurrences after treatment
with curative intent occur during the first year. Thereafter,
patients have a relatively good life expectancy.3 Still,
specific symptoms and functional problems related to
esophageal cancer and its treatment may be persistent.7
Whether patients’ HRQoL is comparable to baseline refer-
ence values for patients with esophageal cancer and to those
for the general population is unknown.
The primary aim of the current studywas to investigate the
long-term HRQoL of patients with esophageal cancer cura-
tively treated with neoadjuvant therapy followed by surgery,
surgery only, or chemoradiation only.Resultswere compared
with reference HRQoL values of a heterogeneous sample of
patients with esophageal cancer in various stages of disease
and of a sample of individuals from the general population.PATIENTS AND METHODS
Patients
Between January 1995 and December 2007, 163 consecutive patients
with cancer of the esophagus underwent a potentially curative treatment
at The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.
Thirty-seven patients with a minimal follow-up of 1 year and without tumor
recurrence were eligible for this study. In April 2009, they were contacted
by a research physician (ECS) and asked for informed consent. One patient
could not be reached because he had emigrated. The remaining 36 patients
agreed to participate in the study.rdiovascular Surgery c Volume 140, Number 4 777
Abbreviations and Acronym
EORTC ¼ European Organization for Research
and Treatment of Cancer
HRQoL ¼ health-related quality of life
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SSociodemographic and Clinical Data
Information on patients’ age at the time of the study, gender, tumor loca-
tion and histology, clinical stage according to TNM classification, type of
treatment, and length of follow-up was obtained from the medical records.
Health-Related Quality of Life
HRQoL was assessed with several self-report questionnaires. These in-
cluded the European Organization for Research and Treatment of Cancer
(EORTC) core questionnaire (QLQ-C30) and the EORTC esophageal
cancer-specific module (QLQ-OES18).8-10 The QLQ-C30 contains 5 func-
tional scales (physical, role, cognitive, emotional, and social), 3 symptom
scales (fatigue, pain, and nausea/vomiting), a global health/quality-of-life
scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation,
diarrhea, and financial difficulties). The QLQ-OES18 contains 4 symptom
scales (dysphagia, eating, reflux, and pain) and 6 single items (trouble swal-
lowing saliva, choking, dry mouth, taste, cough, and speech). All scale and
single items scores range from 0 to 100. A high score for a functional scale
represents a higher (‘‘better’’) level of functioning, whereas a high score for
a symptom scale or item represents a higher (‘‘worse’’) level of symptoms.
A visual analog scale was also used to assess current overall HRQoL, with
higher scores representing better HRQoL (range, 0–100).
Additional study-specific questions assessed patients’ ratings of the
treatment with chemo(radio)therapy or surgery (12 items), body weight
(4 items), body image (4 items), employment status and finances (6 items),
and survivorship issues (eight items).
Statistical Analysis
HRQoL data are presented as mean values with standard deviations.
Both the QLQ-C30 and the QLQ-OES18 scores were compared with base-
line HRQoL data from a large, heterogeneous sample (N¼ 1031) of patients
with esophageal cancer in all stages of disease, including recurrent or met-
astatic disease.11 The patients’ QLQ-C30 scores were also compared with
reference values derived from a general population sample of 7802 individ-
uals.11 No adjustments could be made for differences in sociodemographic
or clinical characteristics because we did not have access to the original data
for these comparison groups.
Student t tests were used to compare mean scores. Because of multiple
testing, P  .01 was considered statistically significant. A Levene test
was performed on all mean comparisons to ensure variance equality. Statis-
tical analyses were conducted using the Statistical Package for the Social
Sciences version 15.0 (SPSS Inc, Chicago, Ill) and R (a free software envi-
ronment for statistical computing and graphics).12
RESULTS
Characteristics of the study sample, the reference group of
patients with esophageal cancer, and the general population
sample are summarized in Table 1. Twenty-one study patients
underwent neoadjuvant therapy followed by surgery, 9 pa-
tients underwent surgery only, and 6 patients underwent che-
moradiation only. The majority of the patients had a tumor
located in the distal esophagus or at the esophagogastric junc-
tion (78%), andhistologywasmostly adenocarcinoma (61%).
Median survival was 54 (interquartile range, 36–124) months.778 The Journal of Thoracic and Cardiovascular SurgHealth-Related Quality of Life
QLQ-C30 mean scores and standard deviations for the
study sample, the patient reference group, and the general
population reference group are presented in Table 2. When
compared with the patient reference group, the patient sam-
ple reported significantly better overall global health/quality
of life (P< .001), better emotional functioning (P ¼ .01),
less pain (P ¼ .005), and less constipation (P< .001), but
more diarrhea (P< .001). Except for cognitive functioning,
diarrhea, and financial difficulties, the patient sample scored
consistently better than the patient reference group for the
remaining function and symptom scales/items, although
differences did not reach statistical significance.
The patient sample scored significantly lower than the
general population reference group on physical functioning
(P¼ .01), fatigue (P¼ .01), nausea/vomiting (P<.001), ap-
petite loss (P<.001), and diarrhea (P<.001). A marginally
statistically significant difference (P<.05) was observed for
cognitive functioning.
Table 3 displays the mean scores and standard deviations
on theQLQ-OES18 for the patient sample and the patient ref-
erence group. The patient sample reported significantly fewer
problems with dysphagia (P< .001), pain (P< .001), and
taste (P< .001) than the patient reference group. Neverthe-
less, it should be noted that half of our patient sample
(n ¼ 18) still reported dysphagia.
Table 4 shows the 10 most frequently reported symptoms.
Themost frequent symptomwas early satiety (n¼ 29; 81%),
and this symptomwas evenmore prevalent (n¼ 28/30; 93%)
when excluding the patients who did not undergo surgery.
The mean score on the EORTC QLQ-C30 global health/
quality of life scale was 77 (19). This was similar to the
score obtained from the visual analog scale HRQoL scale
(76  18).
When comparing patients with stage I or II (n ¼ 16) and
patients with stage III or IV (n ¼ 20), there were no statisti-
cally significant differences in HRQoL (data not shown).Patient Ratings of the Treatment With
Chemo(radio)therapy or Surgery
A majority of patients reported they were well informed
about the treatment they had undergone (Table 5). Treatment
with chemo(radio)therapy was less severe than expected for
70% of evaluable patients, whereas the operation was less
severe than expected for 86% of evaluable patients.Body Weight and Body Image
Patients reported having lost a mean of 9.6 (10) kg
(11%) compared with their body weight 1 year before treat-
ment. Comparedwith their weight at the end of treatment, pa-
tients noted a small mean weight gain of 0.7 (8.0) kg (3%).
In regard to patients’ body image, a majority (78%) of
patients did not feel unattractive, but 18 patients (50%)ery c October 2010
TABLE 1. Patient and tumor characteristics for 36 long-term survivors after potentially curative treatment for esophageal cancer, a reference
group of 1031 patients with esophageal cancer, and a sample of 7802 individuals from the general population
Characteristic Patient sample
Reference group of patients
with esophageal cancer
General population
reference group
Total no. of patients 36 (100%) 1031 (100%) 7802 (100%)
Age at time of survey (y)
<40 – – 9 (1%) 2283 (29%)
40–49 3 (8%) 101 (10%) 1457 (19%)
50–59 9 (25%) 237 (23%) 1593 (20%)
60–69 8 (22%) 346 (34%) 1414 (18%)
70–79 13 (36%) 270 (26%) 741 (10%)
80þ 3 (8%) 68 (7%) 182 (2%)
Not known – – – – 132 (2%)
Gender
Male 23 (64%) 772 (75%) 4046 (52%)
Female 13 (36%) 248 (24%) 3749 (48%)
Not known – – 11 (1%) 7 (0%)
Clinical stage according to
TNM classification
Stage I 4 (11%) 118 (11%) NA
Stage IIA 11 (31%)
Stage IIB 1 (3%)
Stage III 12 (33%) 47 (5%)
Stage IVA 8 (22%)
Stage IVB – –
Recurrent/metastatic – – 347 (34%)
Not known – – 519 (50%)
TNM, Tumor node metastasis; NA, not applicable.
TABLE 2. Mean quality-of-life scores (QLQ-C30) for 36 long-term survivors after potentially curative treatment for esophageal cancer compared
with reference values for patients with esophageal cancer and the general population
Patient sample
(n ¼ 36)
Reference group of
patients with esophageal
cancer (n ¼ 1031)
General population
reference group
(n ¼ 7802)
Score SD Score SD P value 99% CI Score SD P value 99% CI
QLQ-C30
Global health score 77 19 56 24 <.001 10.6 to 31.4 71 22 .1 3.5 to 15.5
Functional scales
Physical functioning 83 15 77 24 .14 4.4 to 16.4 90 16 .01 13.9 to0.1
Role functioning 78 24 69 36 .14 6.6 to 24.6 85 25 .09 17.8 to 3.8
Emotional functioning 81 20 71 24 .01 0.4 to 20.4 76 23 .19 4.9 to 14.9
Cognitive functioning 79 22 83 22 .28 13.6 to 5.6 86 20 .04 15.6 to 1.6
Social functioning 81 23 76 28 .29 7.2 to 17.2 88 23 .07 16.9 to 2.9
Symptom scales/items
Fatigue 35 27 37 27 .66 13.8 to 9.8 24 24 .01 0.7 to 21.3
Nausea/vomiting 15 24 17 23 .61 12.1 to 8.1 4 12 <.001 5.8 to 16.2
Pain 14 25 27 27 .005 24.8 to1.2 21 28 .13 19.0 to 5.0
Dyspnea 16 25 19 27 .51 14.8 to 8.8 12 23 .30 5.9 to 13.9
Insomnia 19 28 30 33 .05 25.4 to 3.4 21 30 .69 14.9 to 10.9
Appetite loss 29 39 34 37 .43 21.2 to 11.2 7 18 <.001 14.2 to 29.8
Constipation 6 15 26 31 <.001 33.4 to6.6 7 18 .74 8.7 to 6.7
Diarrhea 21 32 7 19 <.001 5.5 to 22.5 7 18 <.001 6.2 to 21.8
Financial difficulties 17 29 15 28 .67 10.2 to 14.2 10 23 .07 2.9 to 16.9
QLQ-C30,Quality of Life core questionnaire; CI, confidence interval; SD, standard deviation. A high score for a functional scale represented a high (‘‘better’’) level of functioning,
whereas a high score for a symptom scale or item represented a high (‘‘worse’’) degree of symptoms. Statistically significant results are in bold.
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TABLE 3. Mean quality-of-life scores (QLQ-OES18) for 36 long-term survivors after potentially curative treatment for esophageal cancer
compared with reference values for patients with esophageal cancer
Patient sample (n ¼ 36)
Reference group of patients with
esophageal cancer (n ¼ 1031)
Score SD Score SD P value 99% CI
QLQ-OES18
Symptom scales/items
Dysphagia 26 34 42 28 <.001 28.3 to3.7
Eating 38 30 43 29 .31 17.7 to 7.7
Reflux 21 28 17 25 .35 7.0 to 15.0
Pain 9 16 27 24 <.001 28.4 to7.6
Trouble swallowing saliva 10 26 23 33 .02 27.3 to 1.3
Choking 19 22 18 29 .84 11.6 to 13.6
Dry mouth 19 30 28 34 .12 23.8 to 5.8
Taste 9 22 31 37 <.001 38.0 to6.0
Cough 17 23 20 29 .54 15.6 to 9.6
Speech 6 16 12 25 .15 16.8 to 4.8
QLQ-OES18, Esophageal site-specific questionnaire; CI, confidence interval; SD, standard deviation. A high score represented a high (‘‘worse’’) degree of symptoms. Statistically
significant results are in bold.
General Thoracic Surgery Courrech Staal et alG
T
Sfelt that their appearance was affected by their treatment
(Table 6). There were 2 patients who avoided people be-
cause of their physical appearance.Employment Status and Finances
Before their treatment, 19 patients were retired, 16 pa-
tients had a job (14 in paid employment and 2 as volunteers),
and 1 patient was unemployed. At the time of the survey, 3
additional patients had retired, and 3 patients had been un-
able to continue working. The remaining 10 patients re-
sumed working, although half of them at a reduced level.
Eleven patients (31%) still had additional expenses re-
lated to their disease or its treatment, ranging from 60 to
155 Euros per month. Costs included expenses for medica-TABLE 4. The ten most frequently reported symptoms
Study sample
Symptom
Not at
all (1)
A little
(2)
Quite a
bit (3)
Very
much (4)
Mean
score
(1–4)
Early satiety 7 9 8 12 2.7
Trouble with eating 14 13 3 6 2.0
Trouble with eating
in front of other people
15 9 9 3 2.0
Trouble with enjoying
meals
21 6 3 6 1.8
Acid indigestion/heartburn 23 5 4 4 1.7
Trouble with acid/bile
in your mouth
23 6 6 1 1.6
Dry mouth 23 7 4 2 1.6
Choking when swallowing 18 15 3 – 1.6
Trouble with drinking
liquids
25 6 3 2 1.5
Trouble with coughing 22 10 4 – 1.5
780 The Journal of Thoracic and Cardiovascular Surgtion, special food, complementary therapy, home care, and
adjustments in the house. One patient had experienced trou-
ble obtaining life insurance.
Perceived Health and Future Perspective
Patients’ current self-reported health status was compared
with 3 different time periods (Table 7). Seventeen patients
(47%) reported that their current health status was the
same as before their diagnosis. Twenty-three patients
(64%) rated their current health status as much better than
8 to 12 weeks after completion of the treatment.
Twenty-seven patients (75%) believed that they had been
cured of their disease, and 67% believed they had a life ex-
pectancy similar to that of peers from the general population.
Nevertheless, 19 patients (53%) worried that the disease
might recur (‘‘sometimes’’ to ‘‘always’’).
Temporal Analysis
With regard to time, no statistically significant differences
in QLQ-C30 and QLQ-OES18 scores were observed
between patients with a follow-up of less than 5 years
(n ¼ 21; median survival 37 [interquartile range 27–50]
months) and patients with a follow-up of 5 years or more
(n ¼ 15; median survival 133 [interquartile range,
100–150] months) (data not shown).
DISCUSSION
The present study evaluated the HRQoL of long-term sur-
vivors after potentially curative treatment for esophageal
cancer. The results indicate that (1) these patients reported
better HRQoL than a large reference group of patients
with esophageal cancer, but worse comparedwith a reference
sample from the general population; (2) a variety of symp-
toms continued to persist in the majority of patients; (3)ery c October 2010
TABLE 5. Patient ratings of the treatment with chemo(radio)therapy or surgery
Statement Strongly agree Agree I do not know Disagree Strongly disagree
Chemo(radio)therapy (n ¼ 27)* No. of patients (percentage)
I received sufficient information on possible side effects. 20 (74%) 7 (26%) – – –
I was able to ask enough questions regarding the treatment. 26 (96%) 1 (4%) – – –
The treatment was less severe than expected. 10 (37%) 9 (33%) 3 (11%) 4 (15%) 1 (4%)
The travel time to the hospital was a burden. 4 (15%) 6 (22%) 1 (4%) 6 (22%) 10 (37%)
I was well supported by my doctor during the treatment. 23 (85%) 4 (15%) – – –
The recovery phase did not disappoint me. 10 (37%) 8 (30%) 3 (11%) 6 (22%) –
The period after the treatment was a difficult time. 6 (22%) 13 (48%) 1 (4%) 5 (19%) 2 (7%)
Surgery (n ¼ 30)y
I received sufficient information on possible complications. 22 (73%) 4 (13%) 1 (3%) 2 (7%) 1 (3%)
I was able to ask enough questions regarding the operation. 24 (80%) 4 (13%) – – 2 (7%)
The operation was less severe than expected. 19 (63%) 7 (23%) 3 (10%) 1 (3%) –
The recovery phase did not disappoint me. 11 (37%) 8 (27%) 1 (3%) 9 (30%) 1 (3%)
The period after the operation was a difficult time. 10 (33%) 13 (43%) 1 (3%) 4 (3%) 2 (7%)
*Alone or followed by surgery. yAlone or preceded by chemo(radio)therapy.
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by patients compared with what they expected; (4) treatment
had not seriously affected patients’ body weight or body im-
age; and (5) the majority of patients believed that they had
been cured of their disease and had a life expectancy similar
to that of peers from the general population.
Patients in the present study had survived a potentially
life-threatening cancer. They had experienced an intense
treatment period, but they had recovered. They probably
knew the odds of surviving esophageal cancer, but now
they were long-term survivors. The fact that our patient sam-
ple reported significantly better HRQoL than the reference
patient group can be explained, at least in part, by the fact
that the reference group was composed of patients with all
stages of disease before the start of their treatment. If we
had been able to use a more homogeneous reference group
resembling more closely the current patient sample in terms
of stage of disease and prognosis, the differences that we ob-
served in HRQoL might have been minimized. In fact, ex-
cept for diarrhea and financial difficulties, all scores in the
symptom scales were better in our study sample than in
the patient reference group. After surgery, patients could
have developed post-vagotomy diarrhea, whereas patients
from the reference patient group with recurrent or metastatic
disease could have more symptoms of constipation caused
by analgesic use. Despite the lack of information on exact
stage distribution and treatment modalities in the reference
patient group, these EORTC data on HRQoL are the bestTABLE 6. Body image ratings
Not at all
Item
I felt unattractive in the past week. 28 (78%)
I found it difficult to see myself naked in the past week. 26 (72%)
My physical appearance is affected by the treatment. 18 (50%)
I avoided people because of my physical appearance. 34 (94%)
The Journal of Thoracic and Caavailable reference values derived from a large group of
patients with esophageal cancer.
Most of the HRQoL scores of the patient sample were
worse than those of the general population reference group.
These differences, although likely reflecting residual prob-
lems due to the disease and its treatment, may also be due,
in part, to the fact that our patient sample was older than
the general population sample (eg, 67% were aged  60
years compared with 30% in the general population)
(Table 1). This could also explain why the difference in
physical functioning between the treatment group and the
general population reference group was statistically signifi-
cant, and not in the other functional scales.
Early satiety during a meal was the most frequently re-
ported symptom (81%). This finding is in line with previous
studies that have reported this symptom in 65% to 75% of pa-
tients with esophageal cancer.3,13 After esophageal resection,
early satiety may occur as the result of an increasing pressure
in the gastric tube and a diminished gastric reservoir. In the
current study, 93% of surgically treated patients reported
early satiety.
Most patients reported being well informed about the treat-
ment that was given. Not surprisingly, themajority of patients
experienced the period after treatment as difficult. In retro-
spect, both chemo(radio)therapy and surgerywere rated as be-
ing well tolerated. It can be expected that scores would have
been worse during or shortly after treatment. Seventy percent
of patients, treated with chemo(radio)therapy, indicated thatA little Quite a bit Very much
No. of patients (percentage)
7 (19%) – 1 (3%)
7 (19%) 1 (3%) 2 (6%)
14 (39%) 3 (8%) 1 (3%)
2 (6%) – –
rdiovascular Surgery c Volume 140, Number 4 781
TABLE 7. Perceived health and future perspective
No. of patients and percentage
Much better A little better The same A little worse Much worse
Current health compared with that before the diagnosis 4 (11%) 2 (6%) 17 (47%) 10 (28%) 3 (8%)
Current health compared with that before the start of treatment 11 (31%) 4 (11%) 13 (36%) 7 (19%) 1 (3%)
Current health compared with that 8–12 wks after the treatment 23 (64%) 5 (14%) 6 (17%) 1 (3%) 1 (3%)
Completely true Mostly true I do not know Mostly false Completely false
I am cured of my disease. 27 (75%) 5 (14%) 4 (11%) – –
I have the same life expectancy as other people. 24 (67%) 7 (19%) 4 (11%) – 1 (3%)
I live day to day. 5 (14%) 7 (19%) 4 (11%) 11 (31%) 9 (25%)
I make future plans. 12 (33%) 14 (39%) 3 (8%) 5 (14%) 2 (6%)
Always Mostly Often Sometimes Rarely Never
I fear that my disease will return. 2 (6%) 1 (3%) 4 (11%) 12 (33%) 11 (31%) 6 (17%)
General Thoracic Surgery Courrech Staal et alG
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able, transient, negative effects that chemoradiation can
have onmost aspects ofHRQoLduring and shortly after treat-
ment may explain this result, even though in our study it was
scored at least 1 year after treatment.14-16
The retired portion of the general population is increasing,
and its demographic composition is changing.Many patients
with esophageal cancer belong to this part of the population.
Unfortunately, only half of the patients who were employed
before treatment could resume their work, and those who did
return to work often did so at a reduced level. Similar results
have been reported by de Boer and colleagues.3
Older adults tend to express less positive attitudes toward
their bodies than younger adults.17 Given that the median
age of our sample at study entry was 66 years, it is actually
somewhat surprising that the majority of patients reported
being satisfied with their physical appearance. It may be
that these patients placed less emphasis on body image
than on other issues of greater importance to them after
a potentially life-threatening illness.
Patients’ views on cure and life expectancy seemed to be
somewhat contradictory. On the one hand, the majority of
patients believed that they had been cured. Yet, more than
half of the patients worried that their disease might recur. Al-
though this may suggest that the phrasing of the questions
was not sufficiently clear, it may also reflect a genuine am-
bivalence among patients about their long-term prognosis.
This finding deserves further investigation.
Surprisingly, a comparisonbetween 2 groupswith different
follow-up times showed no statistically significant differ-
ences. It seems that for long-term esophageal cancer survi-
vors, the exact duration of their survival does not influence
quality of life scores.
The strengths of this study include the high response rate
and the use of primarily standardized, validated question-
naires. The high response rate reduced the risk of selection
bias and the use of validated, multidimensional question-
naires protected against information bias.782 The Journal of Thoracic and Cardiovascular SurgStudy Limitations
Several limitations of the study should also be noted. The
sample size was small, precluding the possibility of examin-
ing the extent to which HRQoL varies as a function of type of
treatment. Also, the cross-sectional study design did not
allow us to investigate directly changes in HRQoL over
time, although wewere able to pose some retrospective ques-
tions in this regard. In the case of the general population, there
were differences in age and gender distribution, for which we
did not correct. HRQoL is much more than physical symp-
toms. To overcome this limitation, we have added additional
questions (eg, questions on survivorship issues). Finally, we
did not have sufficient clinical information on the 2 reference
groups to perform risk adjustments of the results. Despite
these shortcomings, the study population is a unique group
of patients with esophageal cancer who survived at least 1
year after potentially curative treatment. Multicenter studies
are needed. It is extremely difficult to accrue large samples
of long-term esophageal cancer survivors from a single cen-
ter, because the overall 5-year survival is still low. The role
of definitive chemoradiation is increasing in the treatment
of this disease.18,19 If chemoradiation, with or without
surgery, results in similar survival to surgery alone, then
HRQoL issues may play an increasingly important role in
treatment decision-making.CONCLUSIONS
Our results indicate that some aspects of HRQoL are
impaired in disease-free patients treated for esophageal
cancer. However, in general, they can lead satisfactory
lives. This information can be used to help inform patients
during the pretreatment period about the long-term effects
of treatment.References
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